The 2011 Import and Export Market for Glycosides, Glands or Other Organs and Extracts, Antisera, Vaccines, and Similar Products in Latvia

On the demand side, exporters and strategic planners focusing on glycosides, glands or other organs and extracts, antisera, vaccines, and similar products in Latvia face a number of questions. Which countries are supplying glycosides, glands or other organs and extracts, antisera, vaccines, and similar products to Latvia? How important is Latvia compared to others in terms of the entire global and regional market? How much do the imports of glycosides, glands or other organs and extracts, antisera, vaccines, and similar products vary from one country of origin to another in Latvia? On the supply side, Latvia also exports glycosides, glands or other organs and extracts, antisera, vaccines, and similar products. Which countries receive the most exports from Latvia? How are these exports concentrated across buyers? What is the value of these exports and which countries are the largest buyers?

This report was created for strategic planners, international marketing executives and import/export managers who are concerned with the market for glycosides, glands or other organs and extracts, antisera, vaccines, and similar products in Latvia. With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics which appear several years after the fact. I have developed a methodology, based on macroeconomic and trade models, to estimate the market for glycosides, glands or other organs and extracts, antisera, vaccines, and similar products for those countries serving Latvia via exports, or supplying from Latvia via imports. It does so for the current year based on a variety of key historical indicators and econometric models.

In what follows, Chapter 2 begins by summarizing where Latvia fits into the world market for imported and exported glycosides, glands or other organs and extracts, antisera, vaccines, and similar products. The total level of imports and exports on a worldwide basis, and those for Latvia in particular, is estimated using a model which aggregates across over 150 key country markets and projects these to the current year. From there, each country represents a percent of the world market. This market is served from a number of competitive countries of origin. Based on both demand- and supply-side dynamics, market shares by country of origin are then calculated across each country market destination. These shares lead to a volume of import and export values for each country and are aggregated to regional and world totals. In doing so, we are able to obtain maximum likelihood estimates of both the value of each market and the share that Latvia is likely to receive this year. From these figures, rankings are calculated to allow managers to prioritize Latvia compared to other major country markets. In this way, all the figures provided in this report are forecasts that can be combined with internal information sources for strategic planning purposes.

After the worldwide summary in Chapter 2 of both imports and exports of glycosides, glands or other organs and extracts, antisera, vaccines, and similar products, Chapter 3 goes into detail on imports, but for each major country of origin serving Latvia. A “major” market is defined as a country where Latvia represents a substantially large share of either imports or exports. For each major country exporting to Latvia, one can thus observe how important Latvia is to that exporting country compared to other countries of the world. Chapter 4 does the same, but for exports of glycosides, glands or other organs and extracts, antisera, vaccines, and similar products originating from Latvia, for each major country of destination. In doing so, one can discover the share that Latvia has in each major market; this share value is often used as a measure of competitiveness for Latvia. In all cases, the total dollar volume and percentage share values by major trading partner are provided. Combined, Chapters 3 and 4 present a the total picture for imports and exports of glycosides, glands or other organs and extracts, antisera, vaccines, and similar products to and from Latvia to and from all other major countries in the world. "Glycosides, Glands or Other Organs and Extracts, Antisera, Vaccines, and Similar Products" as a category is defined in this report following the definition given by the United Nations Statistics Division Classification Registry using the Standard International Trade Classification, Revision 3 (SITC, Rev. 3). The SITC code that defined "glycosides, glands or other organs and extracts, antisera, vaccines, and similar products" is 5416 . SHOW LESS READ MORE >

1 INTRODUCTION AND METHODOLOGY
2 LATVIA AND THE WORLD MARKET
2.1 Imports in Latvia in 2011
2.2 Exports from Latvia in 2011
3 IMPORTS IN LATVIA
3.1 Europe
3.1.1 Czech Republic
3.1.2 Estonia
3.1.3 Finland
3.1.4 Lithuania
3.1.5 Poland
3.1.6 Russia
3.1.7 Slovenia
4 EXPORTS FROM LATVIA
4.1 Europe
4.1.1 Belarus
4.1.2 Estonia
4.1.3 Hungary
4.1.4 Ireland
4.1.5 Lithuania
4.1.6 Sweden
5 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS
5.1 Disclaimers & Safe Harbor
5.2 ICON Group Ltd. User Agreement Provisions